HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adenosine A2A receptor contributes to ischemic brain damage in newborn piglet.

Abstract
Pharmacologic inactivation or genetic deletion of adenosine A2A receptors protects ischemic neurons in adult animals, but studies in neonatal hypoxia-ischemia (H-I) are inconclusive. The present study in neonatal piglets examined the hypothesis that A2A receptor signaling after reoxygenation from global H-I contributes to injury in highly vulnerable striatal neurons where A2A receptors are enriched. A2A receptor immunoreactivity was detected in striatopallidal neurons. In nonischemic piglets, direct infusion of the selective A2A receptor agonist CGS 21680 through microdialysis probes into putamen increased phosphorylation of N-methyl-D-aspartic acid (NMDA) receptor NR1 subunit and Na(+),K(+)-ATPase selectively at protein kinase A (PKA)-sensitive sites. In ischemic piglets, posttreatment with SCH 58261, a selective A2A receptor antagonist, improved early neurologic recovery and preferentially protected striatopallidal neurons. SCH 58261 selectively inhibited the ischemia-induced phosphorylation of NR1, Na(+),K(+)-ATPase, and cAMP-regulated phosphoprotein 32 KDa (DARPP32) at PKA-sensitive sites at 3 hours of recovery and improved Na(+),K(+)-ATPase activity. SCH 58261 also suppressed ischemia-induced protein nitration and oxidation. Thus, A2A receptor activation during reoxygenation contributes to the loss of a subpopulation of neonatal putamen neurons after H-I. Its toxic signaling may be related to DARPP32-dependent phosphorylation of PKA-sensitive sites on NR1 and Na(+),K(+)-ATPase, thereby augmenting excitotoxicity-induced oxidative stress after reoxygenation.
AuthorsZeng-Jin Yang, Bing Wang, Herman Kwansa, Kerry D Heitmiller, Gina Hong, Erin L Carter, Jessica L Jamrogowicz, Abby C Larson, Lee J Martin, Raymond C Koehler
JournalJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (J Cereb Blood Flow Metab) Vol. 33 Issue 10 Pg. 1612-20 (Oct 2013) ISSN: 1559-7016 [Electronic] United States
PMID23860373 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine
  • Adenosine A2 Receptor Agonists
  • Adenosine A2 Receptor Antagonists
  • Phenethylamines
  • Pyrimidines
  • Receptor, Adenosine A2A
  • Triazoles
  • 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
  • Adenosine
Topics
  • Adenosine (administration & dosage, analogs & derivatives, pharmacology)
  • Adenosine A2 Receptor Agonists (administration & dosage, pharmacology)
  • Adenosine A2 Receptor Antagonists (administration & dosage, pharmacology, therapeutic use)
  • Animals
  • Animals, Newborn
  • Blood Flow Velocity (drug effects, physiology)
  • Cerebrovascular Circulation (drug effects, physiology)
  • Corpus Striatum (drug effects, metabolism, pathology)
  • Disease Models, Animal
  • Hypoxia-Ischemia, Brain (metabolism, pathology, physiopathology, prevention & control)
  • Immunohistochemistry
  • Laser-Doppler Flowmetry
  • Male
  • Neurons (drug effects, metabolism, pathology)
  • Oxidative Stress (drug effects)
  • Phenethylamines (administration & dosage, pharmacology)
  • Pyrimidines (administration & dosage, pharmacology, therapeutic use)
  • Receptor, Adenosine A2A (metabolism)
  • Sus scrofa
  • Triazoles (administration & dosage, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: